ASPCF News and Press, Acerus Pharmaceuticals Corp From 06/07/22

TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCD) today announced that it has entered into an amended and restated promissory note (the “ A&R Note ”) ...

Acerus Pharmaceuticals press release (OTCQB:ASPCF): Q1 GAAP EPS of $0.00. Revenue of $0.78M (+239.1% Y/Y). For further details see: Acerus Pharmaceuticals GAAP EPS of $0.00, revenue of $0.78M

TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2022. Unless otherwise noted, all amounts are in US d...

TORONTO, May 05, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCD) will announce its first quarter 2022 financial and operating results on Tuesday, May 10, 2022 before the market opens. The company will also host a conference call on Tuesday, May 10, 2022 at...

TORONTO, April 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) announced that further to its news release from April 19, 2022, the Company’s application to consolidate its common shares (&#...

TORONTO, April 19, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that the Company intends to undertake a consolidation of its outstanding common shares on the basis of one (1) post-c...

TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“ First Gener...

Acerus Pharmaceuticals Corporation (ASPCF) Q4 2021 Earnings Conference Call March 15, 2022 10:00 AM ET Company Participants Bob Motz - Chief Financial Officer Ed Gudaitis - President and CEO Conference Call Participants Presentation Operator Good morning, ladies and gentlemen, and welcome to ...

Acerus Pharmaceuticals press release (OTCQB:ASPCF): Q4 GAAP EPS of -$0.01. Revenue of $0.74M (+174.1% Y/Y). For further details see: Acerus Pharmaceuticals GAAP EPS of -$0.01, revenue of $0.74M

TORONTO, March 15, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and twelve-month period ended December 31, 2021. Unless otherwise noted, all amo...